[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648206":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":26,"centralContacts":33,"locations":39,"responsibleParty":52,"collaborators":56,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":26,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":96,"whyStopped":26,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Vail Health Behavioral Health","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"One 25mg Dose of Psilocybin","EXPERIMENTAL","Participants in this arm will receive one 25mg dose of psilocybin paired with therapeutic support.",[13],"Drug: Psilocybin (Usona Institute)",{"label":15,"type":10,"description":16,"interventionNames":17},"Two 25mg Doses of Psilocybin","Participants in this arm will receive two 25mg doses of psilocybin approximately 4 weeks apart paired with therapeutic support.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Three 25mg Doses of Psilocybin","Participants in this arm will receive three 25mg doses of psilocybin approximately 4 weeks apart paired with therapeutic support.",[13],{"label":23,"type":24,"description":25,"interventionNames":26},"Wait-list Comparator","NO_INTERVENTION","Participants in this arm will not receive psilocybin as part of the main study but will be given the opportunity to receive a single 25mg dose of psilocybin with therapeutic support after their study participation is complete.",null,[28],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":26},"DRUG","Psilocybin (Usona Institute)","25mg capsule of psilocybin",[9,19,15],[34],{"name":35,"role":36,"phone":37,"phoneExt":26,"email":38},"BHIC Study Team","CONTACT","970-855-7374","bhic@vailhealth.org",[40],{"facility":5,"status":26,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":26},"Edwards","Colorado","81632","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-106.5942,39.64499,{"lat":50,"lon":49},{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Charles Raison","Director, Vail Health Behavioral Health Innovation Center",[57,59,61,63,65],{"name":58,"class":6},"Baylor College of Medicine",{"name":60,"class":6},"Steadman Philippon Research Institute",{"name":62,"class":6},"Emory University",{"name":64,"class":6},"University of Wisconsin, Madison",{"name":66,"class":6},"Usona Institute","100648206","phase-1-psilocybin-effects-on-healthy-aging-biomarkers-and-purpose-in-life-100648206",false,"NCT07719088","Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life","An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in Life","LONG-LIFE","Inclusion Criteria:\n\n* English speaking and able to provide informed consent and complete study procedures\n* Medically healthy, as determined by the screening physician, with no significant medical conditions that would interfere with participation or affect the safety of the subject.\n\nExclusion Criteria:\n\n* History or presence of any psychiatric or medical condition that, in the opinion of the investigator, could pose a safety risk, interfere with participation, or confound study results.\n* Abnormal ECG at screening that may increase risk during participation (e.g., prolonged QTc, arrhythmias, or other clinically significant findings as determined by the study physician).\n* Unwilling or unable to discontinue medications that may interfere with study participation, as determined by the investigator.",true,"ALL","60 Years","80 Years",{"count":80,"type":81},50,"ESTIMATED","INTERVENTIONAL",[84],"PHASE1","The LONG-LIFE study is a randomized Phase I, dose-ranging trial designed to evaluate whether psilocybin impacts aging-related biomarkers, cognitive function, and purpose\u002Fmeaning in life in medically stable older adults.\n\nUp to 50 participants will be enrolled aged 60-80 who will be randomized with equal allocation to one of four intervention groups: (1) receipt of one 25 mg dose of psilocybin; (2) receipt of two 25 mg doses of psilocybin separated by four weeks; (3) receipt of three 25 mg doses, with each dose separated by four weeks; or (4) wait-list comparator condition that does not receive psilocybin. Biomarkers of aging, cognitive performance, and behavioral measures will be assessed at baseline and longitudinally over a 12-month follow-up period. The primary endpoint occurs at the Week 16 visit. Participants randomized to the wait-list condition will be offered a single 25 mg dose of psilocybin following conclusion of the 12-month follow-up period.\n\nFindings from this Phase I study will inform dose selection for a Phase II study should results indicate a potential impact of psilocybin on relevant study endpoints.",[87,88,89],"Aging","Longevity","Biomarkers of Aging",[87,88,91,92,93,94,95],"Cognitive Function","Purpose","Meaning","Well-Being","Biomarkers","NOT_YET_RECRUITING","2026-08-13",{"date":99,"type":100},"2026-08-17","ACTUAL",{"date":102,"type":81},"2026-12",{"date":104,"type":81},"2028-12",{"name":54,"class":6},1]